David J. Drutz, MD, Chairman of the Board
Dr. Drutz, who was first elected to our board of directors in January 2010 and has served as Chairman of the Board since October 2011, is the President of Pacific Biopharma Associates, a biopharmaceutical consulting company that he founded in January 1999. Between 2008 and 2015, he served as Director (March 2008-December 2015), Chief Executive Officer (December 2011-June 2014), Executive Chairman (June 2014-December 2015) and Chief Medical Officer (January 2012-December 2015) of DARA BioSciences, an oncology supportive care company located in Raleigh, NC, which was acquired by Midatech Pharma in December 2015. Dr. Drutz served previously as Chairman of Tranzyme, Inc. (NASDAQ:TZYM, 2000-2010) acquired by Ocera Therapeutics (NASDAQ:OCRX); Director of MethylGene, Inc. (TSX:MYG, 2000-2010) acquired by Mirati Therapeutics (NASDAQ:MRTX); and Director of Gentris Corporation (2007-2014), acquired by Cancer Genetics (NASDAQ:CGIX). From 1999 to 2008 he was a general partner with Pacific Rim Ventures, a Tokyo-based international venture capital firm. He is a former member of the Science and Industry Advisory Committee (SIAC) of Genome Canada, which advises Genome Canada’s board of directors regarding genomics investments throughout Canada. Dr. Drutz’s management experience includes tenures as VP Biological Sciences and VP Clinical Research at Smith Kline & French Laboratories, VP Clinical Development at Daiichi Pharmaceutical Corporation, and CEO of Inspire Pharmaceuticals (1995-1998) and Sennes Drug Innovations (1994-1995). Earlier in his career, Dr. Drutz was Professor of Medicine and Chief of the Division of Infectious Diseases at the University of Texas Health Science Center, San Antonio, and prior to that appointment was Assistant Professor of Medicine and Chief of the Division of Infectious Diseases at the University of California, San Francisco/San Francisco General Hospital. Dr. Drutz received his M.D. from the University of Louisville School of Medicine and postgraduate training in internal medicine and infectious diseases at Vanderbilt University School of Medicine, serving subsequently as a research medical officer (infectious diseases) in the U.S. Navy with the rank of Lieutenant Commander. He is certified by the American Board of Internal Medicine, a fellow of the American College of Physicians and the Infectious Diseases Society of America, a member of the American Society of Clinical Oncology and the American Society for Clinical Investigation, and the author of more than 200 peer-reviewed articles, book chapters and abstracts for presentation. We believe Dr. Drutz’s experience in biotechnology investment and service as a board member and qualifications as a physician qualify him to serve as a member of our board of directors.
Philip L. Hodges
Mr. Hodges was first elected to our board of directors in September 2003 and is currently serving as chair of our audit committee. He is Managing Partner of Redmont Capital, a private equity firm located in Birmingham, Alabama, which he joined at its inception in 1997. Redmont Capital is a co-founder of our company. Mr. Hodges’ investment strategy is focused on high growth small businesses within the health care, life science and technology sectors. He currently serves as a director for several of the firm’s portfolio companies. Mr. Hodges holds a Bachelor of Science in Business Administration from the Brock School of Business at Samford University. We believe Mr. Hodges’ experience as a board member, life science investor and co founder qualifies him to serve as a member of our board of directors.
Mitchel Sayare, Ph.D.
Dr. Sayare was appointed to the Company’s Board of Directors in April 2010. Most recently, he served as Chairman and Chief Executive Officer of ImmunoGen, a publicly traded biotechnology company engaged in the research and development of antibody-based cancer therapeutics. During his tenure with ImmunoGen, Dr. Sayare was responsible for leading a successful IPO and raising over $300 million in venture capital and public equity financing for the company. Dr. Sayare also served as President of the 95%-owned ImmunoGen subsidiary, Apoptosis Technology, where he was responsible for managing operations for the organization. Prior to joining ImmunoGen, Dr. Sayare served as Vice President, Development at Xenogen, Inc., a biotechnology company specializing in monoclonal antibody-based diagnostic systems for cancer. In this role he oversaw all research and development, corporate development and investor relations responsibilities for the company. Dr. Sayare earned his Ph.D. in biochemistry from the Temple University School of Medicine and his undergraduate degree from Ursinus College.
Brigadier General (ret.) Klaus O. Schafer, MD, MPH
Brigadier General (ret.), Klaus Schafer, M.D., MPH, has over 30 years of leadership experience, having held senior positions in government and industry. He was first elected to our board of directors in July 2012. As the Deputy Asst. to the Secretary of Defense for chemical and biological defense, a position he held from April 2004 through June 2005, he oversaw the management of the Department of Defense’s $1.0 billion program for vaccine, therapeutics, medical device and sensor development. He retired from the Air Force as the Assistant Surgeon General with extensive experience managing all aspects of large integrated health care delivery systems. Prior private sector experience includes VP of business development for Compressus Inc., a telemedicine start-up, former CEO and co-founder of TessArae LLC, a start-up biotech genetic testing company. He is currently Chief Medical Officer and VP, business development, Health for CACI International, a publicly traded Fortune 1000 company. We believe Dr. Schafer’s experience in government and as a board member and advisor in the health care biodefense industry, as well as his qualifications as a physician and as a biotechnology investor, qualify him to serve as a member of our board of directors.
Derace L. Schaffer, M.D.
Dr. Schaffer is the founder and Chief Executive Officer of The Lan Group, a venture capital firm specializing in healthcare and high technology investments. Dr. Schaffer has been an active co-investor with Mr. Pappajohn for more than fifteen years on a variety of healthcare companies. In addition, Mr. Pappajohn and Dr. Schaffer have worked together on several private healthcare companies, including, Logisticare, Inc. and Source Medical Inc. Dr. Schaffer served as Chief Executive Officer and Chairman of the Board of Ide Imaging Group, P.C. from 1980 to 2001. Dr. Schaffer has served as a director on many healthcare boards of directors including several health systems and more than ten healthcare services and technology companies. Dr. Schaffer received his postgraduate radiology training at Harvard Medical School and Massachusetts General Hospital, where he served as Chief Resident. Dr. Schaffer currently is also a Clinical Professor of Radiology at Weill Cornell Medical College.
John M. Gill
Mr. Gill has served as President and Chief Executive Officer of PharmAthene since March 2015, and has been a member of the Company’s Board of Directors since 2004. Mr. Gill was a co-founder of TetraLogic Pharmaceuticals Corporation and served as its President and Chief Executive Officer from 2003 to 2013. Prior to co-founding TetraLogic Mr. Gill was Executive Vice President, Chief Operating Officer and a Director of 3-Dimensional Pharmaceuticals, a drug discovery and development company that was acquired by Johnson and Johnson during March 2003. Mr. Gill has previously held positions at SmithKline Beecham Corporation, now GlaxoSmithKline, where he served as a member of the Research and Development Executive Committee, Chairman of the Research and Development Operating Committee, Vice President Research and Development Operations and Finance, a founding member and partner of SR One Ltd., Chief Operating Officer of SK&F Nova Pharmaceuticals and earlier in a variety of finance roles. Mr. Gill is a Certified Public Accountant and served in the United States Marine Corps.
President and CEO - See Management Team. We believe Mr. Enright’s service as our Chief Executive Officer and his experience in the biotechnology industry qualifies him to serve as a member of our board of directors.